Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma

April 21, 2021 By Thomas Lamb

Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of tumor size in only a minority of patients. Predicting response to chemotherapy in patients with MPM by using a genetic marker would, therefore, enable patient … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, cisplatin, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

February 16, 2021 By Thomas Lamb

Background:  Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung cancer. We hypothesised that this regimen would … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab

New Options Spark Sequencing and Biomarker Trials in Mesothelioma

February 10, 2021 By Thomas Lamb

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients, said Anne S. Tsao, MD, during a virtual … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: asbestos, chemotherapy, Immunotherapy, mesothelioma, mesothelioma treatments

Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial

January 14, 2021 By Thomas Lamb

Background:  A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, extrapleural pneumonectomy, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Radiotherapy

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

October 2, 2020 By Thomas Lamb

Background:  There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, cisplatin, malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, pemetrexed

[Transforming Growth Factor Alpha] Promotes Chemoresistance of Malignant Pleural Mesothelioma

June 25, 2020 By Thomas Lamb

Background: There is no standard chemotherapy for refractory or relapsing malignant pleural mesothelioma (MPM). Our previous reports nevertheless indicated that a combination of an anthracycline (doxorubicin) and a lysine deacetylase inhibitor (valproic acid, VPA) synergize to induce the apoptosis of MPM cells and reduce tumor growth in mouse … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, malignant pleural mesothelioma (MPM), mesothelioma treatments

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations

May 16, 2019 By Thomas Lamb

Abstract: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive malignancy that typically presents with vague symptoms, ascites, and/or diffuse peritoneal studding. Despite findings of advanced disease within the peritoneal cavity, spread beyond the abdomen is uncommon. Although advances in systemic chemotherapy have been made, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, malignant mesothelioma, mesothelioma, mesothelioma treatments, peritoneal mesothelioma

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.